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esponsibility of InstAbstract Despite signiﬁcant advances in antiretroviral therapy, increasing drug resistance and toxicities
observed among many of the current approved human immunodeﬁciency virus (HIV) drugs indicate a
need for discovery and development of potent and safe antivirals with a novel mechanism of action.
Maturation inhibitors (MIs) represent one such new class of HIV therapies. MIs inhibit a late step in the
HIV-1 Gag processing cascade, causing defective core condensation and the release of non-infectious
virus particles from infected cells, thus blocking the spread of the infection to new cells. Clinical proof-of-
concept for the MIs was established with betulinic acid derived bevirimat, the prototype HIV-1 MI.
Despite the discontinuation of its further clinical development in 2010 due to a lack of uniform patient
response caused by naturally occurring drug resistance Gag polymorphisms, several second-generation
MIs with improved activity against viruses exhibiting Gag polymorphism mediated resistance have been
recently discovered and are under clinical evaluation in HIV/AID patients. In this review, current
understanding of HIV-1 MIs is described and recent progress made toward elucidating the mechanism of
action, target identiﬁcation and development of second-generation MIs is reviewed.
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Figure 2 The processing cascade of HIV-1 Gag polyprotein pre-
cursor. The proteolytic cleavage of HIV-1 Gag polyprotein precursor
via the viral protease is a sequential and high-order event. The
numbers indicated underneath the various precursors show the
cleavage rates of each individual cleavage step relative to that of
CA-SP1 precursor cleavage, the ﬁnal step with the slowest rate of
cleavage in the Gag processing cascade. CA-SP1 cleavage is a primary
target of the HIV-1 maturation inhibitor bevirimat.
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HIV-1 maturation is the ﬁnal step of the virus lifecycle. It involves
two coupled and highly regulated events: immature virus particle
release driven by the viral Gag protein and a proteolytic cleavage
cascade directed by the viral protease (PR). Numerous studies have
shown that maturation is essential for HIV-1 infectivity because
genetic mutations either in Gag or PR that inhibit maturation lead to
the production of non-infectious HIV-1 particles1–7. Pharmacological
intervention in HIV-1 maturation has been successfully explored,
resulting in the discovery and development of two classes of HIV-1
inhibitors. One class of inhibitors, the PR inhibitors (PI), target and
inhibit the enzymatic activity of the HIV-1 PR. This class has 9
FDA-approved inhibitors that are currently used in treating AIDS
patients worldwide. Another class of inhibitors currently under
clinical development binds the Gag substrate and speciﬁcally blocks
PR-mediated Gag cleavage. The compounds that disrupt the Gag
cleavage are designated the maturation inhibitors (MIs) in a way to
differentiate them from the PI.
The ﬁrst-in-class MI is bevirimat, also known as 3-O-(30,30-
dimethylsuccinyl) betulinic acid, PA-457, or MPC-4326 (Fig. 1)8–10.
Bevirimat speciﬁcally inhibits a speciﬁc step in Gag processing:
cleavage of the CA-spacer protein 1 (SP1) intermediate that occurs late
in the Gag cleavage cascade (Figs. 2 and 3). Despite promising data in a
phase IIa clinical trial, further development of bevirimat was suspended
in 2010 due to bevirimat-resistance conferring Gag SP1 polymorphisms
present in approximately 50% of HIV-1-infected patients11.
Considering that a number of review articles on bevirimat, the
prototype HIV-1 MI, have been published12–14, the purpose of this
review is to describe what is known about the HIV-1 MIs with
particular reference to those advances recently made in the mechan-
isms of action, target identiﬁcation and discovery and clinical
development of new generation MIs highly effective against
bevirimat-resistant viruses.2. HIV-1 assembly and maturation
In HIV-1 lifecycle, the Gag precursor protein Pr55Gag drives the
ﬁnal stage of viral replication: assembly and maturation. FollowingFigure 1 The chemical structures of betulinic acid (top panel) and its
derivative bevirimat, 3-O-(30,30-dimethylsuccinyl) betulinic acid (bot-
tom panel).synthesis, Pr55Gag is transported to the plasma membrane where
virus assembly occurs. Through a complex combination of Gag–
lipid, Gag–Gag, and Gag–RNA interactions, a multimeric budding
structure forms at the inner leaﬂet of the plasma membrane. The
budding virus particle is ultimately released from the cell surface
in a process that is promoted by an interaction between the late
domain in the p6 region of Gag and host proteins, most notably the
endosomal sorting factor TSG101 (tumor susceptibility gene 101).
As illustrated in Fig. 2, concomitant with particle release, the viralFigure 3 Mechanism of action of HIV-1 maturation inhibitor
Bevirimat. In panel A, HeLa cells were transfected with pNL4-3 and
cultured in the absence or presence of indicated concentrations of
bevirimat. Two days posttransfection, cells were metabolically labeled
for 2 h with [35S]Met/Cys. Virus lysates were immunoprecipitated
with anti-HIV antibody. The positions of virally encoded proteins p25
and p24 are indicated. Note the accumulation of p25 in the presence of
bevirimat. Panel B is the thin section electron microscope analysis of
virions produced from bevirimat-treated or -untreated HeLa cells
following transfection with pNL4-3 proviral DNA plasmid. Panel C
schematically shows that bevirimat disrupts the CA-SP1 cleavage and
blocks the release of mature CA protein.
Pharmacological intervention of HIV-1 maturation 495PR cleaves Pr55Gag. These processing events generate the mature
Gag proteins matrix (MA), capsid (CA), nucleocapsid (NC), p6,
and two small Gag spacer peptides (SP1 and SP2). Gag cleavage
triggers a structural rearrangement termed maturation, during
which the immature particle transits to a mature virion character-
ized by an electron-dense, conical core. Among the Gag proces-
sing cascade, cleavage of SP1 from the C terminus of CA is the
ﬁnal event required for ﬁnal CA condensation and formation of the
conical core of virus particles 4,7,15.
Virion maturation is essential for the released virus particles to
become infectious and initiate a new round of infection. The
efﬁciencies with which PR cleaves the Gag sequences vary widely,
resulting in a highly ordered Gag processing cascade, so even
partial inhibition of Gag processing profoundly impairs virus
maturation and infectivity. For example, alterations of the amino
acid sequence at the CA protein (i.e., D51A)16 or the CA-SP1
cleavage site disrupted the CA-SP1 processing, resulting non-
infectious virus particles1,4,7,17. Phenotypically, these particles
defective in the CA-SP1 cleavage manifest themselves in the
presence of an extra CA-SP1 band in some biochemical assays
such as Western blotting. Although the mechanisms whereby the
CA-SP1 processing is inhibited remain largely unknown, these
mutant viruses with a defect in CA-SP1 processing are immature
and non-infectious. These observations strongly suggest that the
proper conversion of the CA-SP1 to mature CA protein, a ﬁnal
event in virus assembly and release, is a key step in the formation
of mature and infectious virus particles, making it an attractive
target for therapeutic development.Figure 4 The clustering of bevirimat-resistance-conferring mutation
at the CA-SP1 cleavage site.3. Identiﬁcation of small molecule inhibitors of HIV-1
maturation
Bevirimat, the prototype HIV-1 MI, was identiﬁed in a blind drug-
screening assay through analyzing natural products coupled with
an activity-directed structural modiﬁcation effort18. Bevirimat, also
called PA-457 or DSB or MPC-4326, is a derivative of betulinic
acid, a weakly active anti-HIV-1 principle in Syzigium claviforum,
an herb used in traditional Chinese medicine. When modiﬁed by
addition of a dimethyl-succinyl moiety at the 30-hydroxy position
to yield bevirimat (3-O-(30,30-dimethylsuccinyl) betulinic acid)
(Fig. 1), in vitro anti-HIV-1 activity was increased by 41000
fold8,18. Bevirimat has potent antiviral activity against multiple
wild-type and drug-resistant clinical HIV-1 isolates with an IC50
(50% inhibitory concentration) of about 10 nmol/L8. Despite
potent activity against HIV-1, bevirimat is inactive against HIV-
2 and Simian immunodeﬁciency virus (SIV).
Initial efforts have identiﬁed that bevirimat disrupts a late step in
Gag processing (Fig. 3) involving conversion of the CA precursor
(CA-SP1) to mature CA8,19. Virions from bevirimat-treated cultures are
non-infectious and exhibit an aberrant particle morphology character-
ized by a spherical, acentric core and a crescent-shaped, electron-dense
shell lying just inside the viral membrane (Fig. 3). Although bevirimat
speciﬁcally disrupts CA-SP1 cleavage, it has been shown that the
compound does not affect the viral PR function8,19. Moreover,
consistent with the effect on Gag processing, the determinants of
bevirimat activity map to amino acid residues ﬂanking the Gag CA-
SP1 cleavage site8–10,19–22. Bevirimat represents a novel class of anti-
HIV compounds termed MIs that exploit a previously unidentiﬁed viral
target.
In 2009, nearly 10 years after bevirimat was identiﬁed, another
chemical compound, 1-[2-(4-tert-butylphenyl)-2-(2,3-dihydro-1H-inden-2-ylamino)ethyl]-3-(triﬂuoromethyl)pyridin-2(1H)-one, named
PF-46396, emerged as a potent anti-HIV-1 drug candidate through a
mechanism similar to what is described for bevirimat23. It is
intriguing to note that bevirimat and PF-46396 are different in
chemical structure but both inhibit HIV-1 replication by disruption of
CA-SP1 processing. This new addition to the HIV-1 MI strongly
indicates that small molecules with diverse chemical classes can
inhibit HIV-1 maturation pathway, further demonstrating the feasi-
bility of CA-SP1 processing as a viable target for anti-HIV drug
discovery.
4. Mechanism of action of HIV-1 MIs
4.1. Genetic determinants of anti-HIV-1 activity of bevirimat
Early stage studies on bevirimat's mechanism of action were
focused largely on extensive characterization of bevirimat-resistant
mutants that evolved during serial passage of HIV-1 at a
suboptimal drug concentration. This method is considered the
gold standard for the identiﬁcation of mutation-mediated resistance
to new drugs toward the elucidation of genetic determinants of
antiviral activity. Work by several laboratories including our own
group identiﬁed six amino acid changes (proximal to CA-SP1
cleavage site) (Fig. 4) that independently confer bevirimat
resistance in the absence of any change in viral PR and other
regions of Gag8,10,19,20. Three substitutions were located at the 1st
and 3rd residues of SP1 (A1V, A3V and A3T) and other three
substitutions were identiﬁed at the extreme C-terminus of CA
(H226Y, L231M and L231F). Mutations CA-H226Y, CA-L231F,
CA-L231M and SP1-A1V do not impose a signiﬁcant replication
defect on HIV-1 in cell culture. In contrast, mutations SP1-A3V
and -A3T severely impaired virus replication and inhibited virion
core condensation. The replication defect imposed by SP1-A3V
was reversed by a second-site compensatory mutation in CA (CA-
G225S). Intriguingly, high concentrations of bevirimat enhanced
the maturation of SP1 residue 3 mutants as evidenced by the
presence of condensed morphology in the majority of released
virions20. The increased core condensation observed with SP1-
A3V at a high concentration of bevirimat is also consistent with
the enhancement in virus replication kinetics seen for SP1-A3V in
the presence of the compound. Taken together, the clustering of
bevirimat-resistance-conferring mutations at the CA-SP1 site
further conﬁrms that CA-SP1 region is the major target for
bevirimat (Fig. 4). This conclusion is also supported and extended
by a comprehensive analysis of a panel of mutant viruses with
point deletions spanning the CA-SP1 cleavage region for their
susceptibility to bevirimat treatment9. This study showed that
bevirimat is a speciﬁc inhibitor of CA-SP1 cleavage and identiﬁed
the CA-SP1 region as the primary viral determinant for this novel
inhibitor of HIV-1 replication9.
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also performed for PF-46396. Interestingly, a single amino acid
substitution in the CA position 201 (CA I201V), distal to the CA-
SP1 cleavage site, was found to confer signiﬁcant resistance to PF-
4639623. This mutation was also sufﬁcient to confer resistance
to bevirimat. On the other hand, bevirimat-resistant SP1-A1V
mutation was capable of rendering viruses resistant to PF-46496.
Cross-resistance between these two MIs suggests that they act
through a similar mechanism, despite that bevirimat and PF-48396
have distinct structures.4.2. Antiviral activity by bevirimat is dependent on a high-order
oligomeric Gag structure
Bevirimat exerts its anti-viral effect in cell culture by inhibiting the
conversion of CA-SP1 to CA protein. However, the in vitro
synthetic peptide-based PR cleavage assay, widely recognized as
the gold standard screening assay for identifying PR inhibitors,
failed to replicate bevirimat-induced defect in CA-SP1 processing.
Likewise, an in vitro recombinant Gag processing experiment was
also incapable of recapitulating the inhibition of CA-SP1 proces-
sing by bevirimat. These observations led to a hypothesis by our
group and others that bevirimat activity is dependent upon a
higher-order Gag structure, which is transiently present during the
Gag assembly process but is not formed in either the synthetic
peptide or recombinant Gag protein8,19. The hypothesis was
further supported by other ﬁndings22,24 in that bevirimat-
mediated inhibition of CA-SP1 processing could be reproduced
in an in vitro Gag processing assay if puriﬁed HIV-1 immature
viral core or assembled HIV-1 Gag chimera containing the Mason-
Pﬁzer monkey virus (M-PMV) p12 domain was provided,
respectively, as a substrate. These elegant in vitro approaches
have played a signiﬁcant role in better understanding of the
mechanism of action of bevirimat.
The distinct phenotypes associated with the mutants described
to date imply the existence of multiple mechanisms by which
HIV-1 can acquire resistance to bevirimat20,22,24. The mutant
L231F signiﬁcantly reduced bevirimat incorporation into immature
particles as measured in liquid chromatography–mass spectrometry
(LC-MS), indicating that mutations in the CA-SP1 region can
confer bevirimat resistance by preventing an interaction between
bevirimat and Gag. While this may be a feasible resistance
mechanism for some of the mutants isolated, the bevirimat
enhancement effect observed for SP1-A3V and -A3T suggests
that these mutations do not block bevirimat binding to Gag but
rather alter the consequences of binding20. The effect of bevirimat
binding to these mutants likely promoted, rather than disrupted,
virion maturation. An alternative mechanism by which mutations
in the CA-SP1 region could confer resistance to bevirimat might
be through signiﬁcantly altering the rate of PR-mediated proces-
sing at the CA-SP1 cleavage site to render processing insensitive
to bevirimaT24. Amino acid substitutions in HIV-1 Gag processing
sites have been shown to inhibit or enhance the rate of proteolytic
processing. The SP1-A1V mutation caused an increase in the
degree of CA-SP1 cleavage relative to wild-type HIV-1 both in
cells and in an in vitro assembly system, suggesting that the
increased CA-SP1 processing rate may contribute to bevirimat
resistance development20,24.
Interestingly, all of the amino acid positions to which bevirimat
resistance maps overlap a CA-SP1 region of the Gag protein
predicted to exhibit α-helical secondary structure1,17. Thisstructure has been visualized as a six-helix bundle within the
immature Gag particles15. Six-helix bundle of CA-SP1 plays an
important role in HIV-1 assembly and budding based on the
observation that the introduction of structure-disrupting mutations
into this region of Gag results in a defect in virus particle
production1,17. While the molecular determinant of bevirimat
activity maps to this six-helix bundle, the compound exhibits no
discernible effect on virus assembly and budding8,9. A possible
explanation for this observation involves the mechanism(s) by
which bevirimat binds the CA-SP1 region in the context
of six-helix bundle and disrupts CA-SP1 processing without
interfering with the assembly function of the putative structural
elements.4.3. Molecular target of bevirimat
The precise mechanism by which bevirimat prevents cleavage of
CA-SP1 has not been fully elucidated; however, a large body
of experimental data appears to suggest that the CA-SP1 junction
of an oligomeric form of Gag within the immature particles is
molecular target of bevirimat8–10,19–22,24,25. Two working models
have been proposed to explain how bevirimat blocks processing of
CA-SP1 cleavage site. The ﬁrst model simply predicts that the
compound inhibits CA-SP1 cleavage site by directly blocking
access of viral PR to the CA-SP1 cleavage site. The second and
perhaps more complex model would be that bevirimat binds to
CA-SP1 junction-derived six-helix bundle and alters the confor-
mation of six-helix bundle (stabilizing Gag CA-SP1 structure) so
that it becomes refractive to cleavage by viral PR. Two indepen-
dent lines of evidence seem to support the second model. First, a
study of bevirimat-treated HIV-1 viral particles by cryo-electron
tomography elegantly demonstrated that the compound likely
stabilizes the immature Gag (CA-SP1) lattice through its interac-
tion with Gag25. This allosteric effect likely induces a structural
transition of CA-SP1 into a stage in which the cleavage of CA-SP1
by viral PR is inhibited. Second, biochemical analysis of
bevirimat-treated HIV-1 virions revealed a slow kinetics in the
formation of the mature viral core19.
In addition to unavailable high-resolution structural data for the
entire Gag including CA-SP1 junction, another obstacle that has
hindered the identiﬁcation of a molecular target for bevirimat is a
lack of a drug–target binding assay. Bevirimat was previously
shown to be incorporated into HIV-1 Gag particles but a direct
interaction between bevirimat and Gag was not demonstrated22.
This challenge has not been resolved until an approach with
combination of photoactivatable bevirimat-derived analogues and
mass spectrometry that was developed in 201126. This approach
involves a crosslinking event that covalently attaches photoacti-
vatable bevirimat analogues to immature HIV-1 Gag particles,
which is subject to further mass spectrometry analysis. Interest-
ingly, in addition to the CA-SP1 region, the major homology
region (MHR) of CA was also identiﬁed to interact with bevirimat
analogues. The MHR of CA has been recently identiﬁed as one of
three critical determinants for antiviral activity that is mediated by
structurally different PF-46396 that has a similar mode of action to
that of bevirimat27. Other two determinants are CA amino acid 201
and CA-SP1 junction. Collectively, these results suggest that three
regions in the assembled Gag constitute a binding pocket present
in a non-linear fashion for the HIV-1 MIs. These data also
implicate that bevirimat and PF-46396 interact differentially with
this putative pocket27.
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The initial results of evaluating bevirimat efﬁcacy in HIV-1/AIDs
patients were promising. In multiple phase II clinical trials
bevirimat was shown to be both safe and effective with viral load
reductions of about 2logs observed in many patients11,28,29. These
data establish a clinical proof of concept for the HIV-1 MI
bevirimat. However, it was also observed in these studies that
the antiviral response to bevirimat was not uniform, with some
patients experiencing a signiﬁcant drop in viral load while others
showed little or no reduction11. Genotypic analyses of these
nonresponsive patients' HIV-1 isolates identiﬁed three key poly-
morphic sites in SP1 (Q6, V7 and T8) involved in bevirimat
resistance (Fig. 5). These three residues (QVT) are referred to the
Gag SP1 polymorphism motif as a whole. Additional bevirimat
resistance polymorphism has been identiﬁed in CA amino acid 362
in patients without prior exposure to bevirimat30 (Fig. 5). Intrigu-
ingly, these bevirimat resistance-conferring mutations in natural
HIV-1 isolates were not identiﬁed in cell culture-based drug
resistance selection experiments. Further studies have showed that
V7 polymorphism is a primary determinant of naturally occurring
resistance to bevirimat and is responsible for the majority
of instances where a lack of sensitivity to bevirimat was
observed31,32. Prevalence of V7 polymorphism as high as 50%
in HIV-1 isolates particular in non-B subtypes had made450% of
HIV-1/AIDS patients not responding to bevirimat treatment in
clinical trials, even though these patients had sufﬁcient plasma
concentrations of the compound. As a result of these observations,
clinical development of bevirimat was discontinued in June 2010.6. Second generation HIV-1 MIs
As a ﬁrst-in-class MI, bevirimat has several unique features
including potent antiviral activity, novel mechanism of action,
effectiveness against HIV-1 strains resistant to currently approved
antiretroviral drugs, and attractive pharmacological and safety
proﬁles as demonstrated in both animal models and human trials.
These desirable attributes have promoted several industry groups
to develop second-generation HIV-1 MIs with the primary goal of
overcoming the challenge of drug resistance associated with
naturally occurring Gag polymorphisms that has halted further
clinical development of bevirimat. Through extensive medicinal
chemistry efforts, a number of lead compounds in second-
generation class of HIV-1 MIs with improved activity against
viruses containing SP1 polymorphisms were discovered and are
currently under clinical development at various stages.
DFH Pharma has identiﬁed a number of second-generation
bevirimat-derived HIV-1 MIs (http://www.croiconference.org/).
Preliminary data showed that these bevirimat derivatives withFigure 5 Gag CA-SP1 polymorphisms that are associated with
bevirimat resistance in HIV/AIDS patients. Two polymorphism sites
found in patients (Gag 362 position in CA and SP1 6-8 positions
QVT) are highlighted with the underlined black letters. Among them,
SP1 V7A polymorphism is a primary determinant of non-responsive-
ness in patients to bevirimat treatment in clinical trials.modiﬁcations at the C-28 position overcame bevirimat resistance
conferred by Gag SP1 polymorphisms, especially those occurring
at SP1 residue 7. Bristol-Myers Squibb (BMS) recently described
a potent second generation inhibitor, dubbed as BMS-955176,
which is very active against bevirimat-resistant SP1 polymorphic
viruses (http://www.bms.com/). BMS-955176 just completed its
antiviral efﬁcacy in a pilot clinical trial with 60 patients enrolled.
Despite the chemical structure of this promising inhibitor
unavailable, the new drug reduced HIV-1 viral load by almost
two orders of magnitude in a 10-day monotherapy trial involving
Clade B patients. A clinical trial involving Clade C patients is
currently ongoing and is expected for the completion later in 2015.
BMS-955176 is very safe without causing any serious
consequences to the patients. GlaxoSmithKline (GSK) has also
invested extensive effort and time in developing second-generation
HIV-1 MIs (http://www.gsk.com/). One leading compound GSK
2828232 has an IC50 of 0.8–4.3 nmol/L against a panel of 26
HIV-1 isolates that contain SP1 polymorphisms including those
present at SP1 7 position. GSK 2828232 has recently entered
multiple-dose Phase I studies for examining its safety and food and
drug interactions in healthy volunteers.7. Conclusions and future prospects
After an exhaustive ﬁve-year research, the HIV-1 MI program has
achieved a signiﬁcant milestone. Several leading drug candidates
in the second-generation MI family have successfully overcome
Gag CA-SP1 polymorphisms-associated resistance problems that
have long challenged and eventually led the discontinuation of the
clinical development of bevirimat. These new MIs are currently at
various stages of the clinical development. Clinical proﬁle of
safety and pharmacokinetics is very desirable that certainly
justiﬁes the further clinical development of these second genera-
tion inhibitors. If successfully in future clinical trials, HIV-1 MIs
will emerge as a new class of antiretroviral armamentarium for
treatment of patients, especially those who harbor viruses resistant
to all approved drugs.
Safety and efﬁcacy demonstrated by past and present HIV-1
MIs with diversiﬁed chemical structures clearly reinforce that the
Gag protein, a primary driving force of virus assembly and
maturation, can be further explored as targets for development
of HIV/AIDS therapeutics. During the maturation process, multi-
ple cleavage events including CA-SP1 sequentially take place. The
identiﬁcation of the CA-SP1 cleavage site as a validated drug
target clearly opens the door to other cleavage sites. Consistent
with this prediction, a high-throughput screening assay for the
identiﬁcation of HIV-1 Gag MA-CA cleavage site has been
developed and recently used in screening 24,000 compounds33.
While none of the compounds discovered were active in inhibiting
the MA-CA cleavage in the secondary assay, extension of the
screening effort to more diverse chemical libraries may enhance a
chance to discover potent inhibitor of this cleavage event.
An intricate interplay between Gag and PR is the primary
determinant of proper HIV-1 maturation, which is exempliﬁed by
documented coevolution of PR and its Gag substrate.
Mutations in PR caused by either low-ﬁdelity viral reverse
transcriptase or use of PIs in treating AIDS patients seem to drive
the emergence of mutations in Gag cleavage sites or Gag regions
distal to cleavage sites. Primary mutations in PR, and corresponding
(compensatory) mutations in Gag, work in concert to maintain
critical interactions between mutated PR and Gag proteins, ensuring
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allowing HIV-1 to evade PI-mediated suppression. Interestingly,
extensive characterization of bevirimat-resistant viruses revealed
multiple mutations occurring only in the CA-SP1 region of Gag,
not in PR. This result is consistent with the observations that Gag
mutations alone have little or no substantial effects on susceptibility
of HIV-1 to PIs. Nevertheless, the impact of PR mutations on the
development of HIV-1 resistance to bevirimat is not clearly under-
stood, which should be investigated in future study.
Identiﬁcation of residues in Gag that comprises the putative
binding pocket of MIs represents a signiﬁcant advance in the ﬁeld.
As with the traditional approach to elucidate the precise mechan-
ism of action and identify a binding pocket of a drug, a real-time
visualized complex consisting of the MI and its target (i.e.,
assembled Gag), either through the crystallography or high-
resolution electron tomography or nuclear magnetic resonance
approach, is eventually needed to better deﬁne the molecular basis
for MI activity as well as to conduct a rational-based design of
new MIs with improved potency and breadth of antiviral activity.
Biophysical tools that measure a drug–Gag interaction are
largely dependent on mass spectrometry or radiolabeling assay.
In either case, it only detects a physical association between drug
and Gag in an indirect fashion. Another shortcoming is that two
assays are not very robust and have a limitation in the high-
throughput potential. Direct binding assays, such as free-label
surface plasmon resonance-based biosensors (i.e., Biacore) or
isothermal titration calorimetry, should be developed and har-
nessed to study HIV-1 MIs. These assays can provide real-time
measurements for kinetics and thermodynamics of drug-Gag
interactions and offer novel insights on the mechanisms of action
and resistance for MIs that are currently in clinical trials.
Another immediate need is to further understand resistance
mutations and patterns that will evolve in response to treatment of
patients by second-generation inhibitors. It has been well estab-
lished that new inhibitors are active against viruses containing CA-
SP1 polymorphisms (Gag 362 and SP1 7 positions) that failed the
ﬁrst generation inhibitor bevirimat. It is still not clear which
polymorphisms or mutations in HIV-1 Gag can render viruses
non-responsive to second-generation MIs. This issue can be
complex because several drug candidates with diverse structures
may bind to Gag differently and mutations that will arise in
patients may get diversiﬁed. Drug resistance information in terms
of individual mutations, mutation patterns and at which frequency
resistant viruses emerge in patients is perhaps not available until
clinical trials that get scaled-up with extended dosing period.
In summary, MIs are a new class of HIV drugs with an attractive
clinical development proﬁle. Clinical proof-of-concept demonstrated
by the ﬁrst-in-class MI bevirimat and reappearance of second-
generation drug candidates with improved breadth and potency in
clinical trials strongly suggest that in the near future multiple MIs
can be approved and used for treatment of HIV/AIDS patients.Acknowledgments
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